Health ❯ Clinical Trials

Drug Efficacy

Weight Loss Drugs Weight Loss Studies Weight Loss Patient Outcomes Cardiovascular Health Phase 3 Trials ESSENCE Trial Lenacapavir Studies Linzagolix Toxicity Studies Safety and Tolerability Preventive Treatments Antiretroviral Drugs Weight Loss Treatments Orforglipron Type 1 Diabetes Treatment Dosing Strategies Anti-fibrotic Treatments Biomarkers FDA Approval Infection Prevention GLP-1 Therapies Mounjaro Trials Phase Trials Ozempic Trials Medical Results HIV Research Medical Needs

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

The lead asset SYH2082 is progressing into Phase 1 following the signing.

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

Small Molecule Blocks RAGE–DIAPH1 Pathway, Reduces Diabetic Tissue Damage in Mice

South Africa Approves Twice-Yearly HIV Prevention Shot, Clearing Path to 2026 Rollout

Amgen Reports Repatha Cuts First-Event Risk in Primary-Prevention Trial

Roche to Acquire 89bio in Deal Worth Up to $3.5 Billion

Maze Therapeutics Reports Strong Phase 1 Signal for MZE782, Announces $150 Million Private Placement

WHO Endorses Twice-Yearly HIV Prevention Jab as Early Adopters Plan 2026 Rollout